| **Sex: Male** | **Total Instances Observed** | **Incidence Range** |
| --- | --- | --- |
| **Tissue** | **Observation** | **Cambodian** | **Chinese** | **Vietnamese** | **Cambodian**  | **Chinese**  | **Vietnamese**  |
| Kidneys | Anomaly (Developmental) | 1 (0.38%), N=262 | 5 (0.72%), N=695 | 1 (0.83%), N=121 | [0-16.67%] | [0-33.33%] | [0-20.00%] |
| Basophilic Tubule | 12 (4.58%), N=262 | 18 (2.59%), N=695 | 7 (5.79%), N=121 | [0-40.00%] | [0-75.00%] | [0-60.00%] |
| Cast | - | 5 (0.72%), N=695 | 1 (0.83%), N=121 | - | [0-25.00%] | [0-20.00%] |
| Cyst | 1 (0.38%), N=262 | 3 (0.43%), N=695 | 1 (0.83%), N=121 | [0-11.11%] | [0-20.00%] | [0-20.00%] |
| Degeneration/Necrosis | 2 (0.76%), N=262 | - | - | [0-20.00%] | - | - |
| Dilatation (Glomerulus) | 1 (0.38%), N=262 | 1 (0.14%), N=695 | - | [0-20.00%] | [0-20.00%] | - |
| Dilatation | - | 4 (0.58%), N=695 | 2 (1.65%), N=121 | - | [0-22.22%] | [0-20.00%] |
| Edema | - | 1 (0.14%), N=695 | - | - | [0-16.67%] | - |
| Fibrosis | 2 (0.76%), N=262 | 5 (0.72%), N=695 | 1 (0.83%), N=121 | [0-20.00%] | [0-33.33%] | [0-20.00%] |
| Glomerulopathy | - | 2 (0.29%), N=695 | - | - | [0-33.33%] | - |
| Glomerulosclerosis | - | 1 (0.14%), N=695 | - | - | [0-33.33%] | - |
| Granuloma | - | 1 (0.14%), N=695 | - | - | [0-25.00%] | - |
| Hemorrhage | 1 (0.38%), N=262 | - | 1 (0.83%), N=121 | [0-20.00%] | - | [0-20.00%] |
| Infarct | - | 1 (0.14%), N=695 | - | - | [0-100.00%] | - |
| Infiltrate, (Mononuclear Cell) | 112 (42.75%), N=262 | 301 (43.31%), N=695 | 59 (48.76%), N=121 | [0-100.00%] | [0-100.00%] | [0-100.00%] |
| Inflammation (Pelvis) | - | 1 (0.14%), N=695 | - | - | [0-20.00%] | - |
| Inflammation (Tubulointerstitial) | - | 3 (0.43%), N=695 | - | - | [0-60.00%] | - |
| Inflammation (Vascular) | - | 1 (0.14%), N=695 | - | - | [0-20.00%] | - |
| Inflammation | 7 (2.67%), N=262 | 9 (1.29%), N=695 | - | [0-80.00%] | [0-33.33%] | - |
| Mineralization | 2 (0.76%), N=262 | 13 (1.87%), N=695 | 3 (2.48%), N=121 | [0-16.67%] | [0-66.67%] | [0-20.00%] |
| Pyelonephritis | - | 1 (0.14%), N=695 | - | - | [0-20.00%] | - |
| Vacuolation (Tubular) | 1 (0.38%), N=262 | 5 (0.72%), N=695 | - | [0-33.33%] | [0-100.00%] | - |
| Vacuolation (Urothelial) | 1 (0.38%), N=262 | 1 (0.14%), N=695 | - | [0-33.33%] | [0-16.67%] | - |
| Ureters | Dilatation | - | 2 (0.93%), N=215 | - | - | [0-33.33%] | - |
| Infiltrate, (Mononuclear Cell) | - | - | 1 (1.18%), N=85 | - | - | [0-11.11%] |
| Urinary Bladder | Cyst | - | 1 (0.17%), N=597 | - | - | [0-25.00%] | - |
| Degeneration/Necrosis | - | 1 (0.17%), N=597 | - | - | [0-16.67%] | - |
| Fibrosis | - | 1 (0.17%), N=597 | - | - | [0-16.67%] | - |
| Infiltrate, (Eosinophils) | - | - | 1 (1.02%), N=98 | - | - | [0-11.11%] |
| Infiltrate, (Mononuclear Cell) | 35 (15.49%), N=226 | 87 (14.57%), N=597 | 12 (12.24%), N=98 | [0-100.00%] | [0-100.00%] | [0-50.00%] |
| Inflammation | 1 (0.44%), N=226 | - | - | [0-16.67%] | - | - |
| Mineralization | - | 1 (0.17%), N=597 | - | - | [0-20.00%] | - |
| Vacuolation (Urothelial) | - | 1 (0.17%), N=597 | - | - | [0-14.29%] | - |

| **Sex: Female** | **Total Instances Observed** | **Incidence Range** |
| --- | --- | --- |
| **Tissue** | **Observation** | **Cambodian** | **Chinese** | **Vietnamese** | **Cambodian**  | **Chinese**  | **Vietnamese**  |
| Kidneys | Anomaly (Developmental) | 4 (1.59%), N=252 | 2 (0.29%), N=685 | - | [0-20.00%] | [0-20.00%] | - |
| Basophilic Tubule | 6 (2.38%), N=252 | 16 (2.34%), N=685 | 6 (4.92%), N=122 | [0-33.33%] | [0-100.00%] | [0-33.33%] |
| Cast | - | 2 (0.29%), N=685 | 2 (1.64%), N=122 | - | [0-20.00%] | [0-20.00%] |
| Cyst | 2 (0.79%), N=252 | 2 (0.29%), N=685 | - | [0-25.00%] | [0-20.00%] | - |
| Degeneration/Necrosis | - | 1 (0.15%), N=685 | - | - | [0-20.00%] | - |
| Dilatation | 1 (0.4%), N=252 | 7 (1.02%), N=685 | - | [0-20.00%] | [0-22.22%] | - |
| Edema | - | 2 (0.29%), N=685 | - | - | [0-16.67%] | - |
| Fibrosis | 1 (0.4%), N=252 | 4 (0.58%), N=685 | - | [0-25.00%] | [0-20.00%] | - |
| Glomerulopathy | - | 1 (0.15%), N=685 | - | - | [0-33.33%] | - |
| Glomerulosclerosis | - | 2 (0.29%), N=685 | 1 (0.82%), N=122 | - | [0-20.00%] | [0-20.00%] |
| Hemorrhage | 1 (0.4%), N=252 | 2 (0.29%), N=685 | - | [0-20.00%] | [0-16.67%] | - |
| Infarct | 1 (0.4%), N=252 | - | 1 (0.82%), N=122 | [0-16.67%] | - | [0-16.67%] |
| Infiltrate, (Mononuclear Cell) | 108 (42.86%), N=252 | 326c\*\* (47.59%), N=685 | 66c\*\* (54.1%), N=122 | [0-100.00%] | [0-100.00%] | [0-100.00%] |
| Inflammation (Tubulointerstitial) | - | 5 (0.73%), N=685 | - | - | [0-60.00%] | - |
| Inflammation | 7 (2.78%), N=252 | 8 (1.17%), N=685 | 2 (1.64%), N=122 | [0-80.00%] | [0-60.00%] | [0-20.00%] |
| Lipidosis, Glomerular | - | 1 (0.15%), N=685 | - | - | [0-25.00%] | - |
| Macrophages | 1 (0.4%), N=252 | - | - | [0-16.67%] | - | - |
| Mineralization | 8 (3.17%), N=252 | 23 (3.36%), N=685 | 7 (5.74%), N=122 | [0-28.57%] | [0-66.67%] | [0-33.33%] |
| Neovascularization | - | 1 (0.15%), N=685 | - | - | [0-20.00%] | - |
| Vacuolation (Tubular) | - | 4 (0.58%), N=685 | - | - | [0-100.00%] | - |
| Vacuolation (Urothelial) | 1 (0.4%), N=252 | 1 (0.15%), N=685 | - | [0-33.33%] | [0-25.00%] | - |
| Ureters | Infiltrate, (Mononuclear Cell) | - | - | 1 (1.18%), N=85 | - | - | [0-20.00%] |
| Urinary Bladder | Adhesion/Inflammation/Fibrosis | - | 1 (0.17%), N=597 | - | - | [0-25.00%] | - |
| Cyst | - | - | 1 (1.02%), N=98 | - | - | [0-11.11%] |
| Degeneration/Necrosis | - | 1 (0.17%), N=597 | - | - | [0-16.67%] | - |
| Hyaline Droplets, Increased | 1 (0.46%), N=219 | - | - | [0-20.00%] | - | - |
| Infiltrate, (Eosinophils) | - | 1 (0.17%), N=597 | - | - | [0-16.67%] | - |
| Infiltrate, (Mononuclear Cell) | 29 (13.24%), N=219 | 80 (13.4%), N=597 | 10 (10.2%), N=98 | [0-75.00%] | [0-100.00%] | [0-50.00%] |
| Inflammation | 1 (0.46%), N=219 | - | - | [0-16.67%] | - | - |
| Vacuolation (Urothelial) | - | 4 (0.67%), N=597 | - | - | [0-42.86%] | - |